Glytec's proposed Glucommander Pediatrics—an insulin-dosing algorithm for hospitalised newborns and infants under two—has received FDA breakthrough device designation. The tool is targeted at neonates who require continuous IV insulin for severe conditions such as DKA and hyperglycaemia of prematurity. The prescription-only product would be separate from Glytec's existing platform and aims to bring proven, technology-enabled insulin titration benefits to NICUs and PICUs.
FDA Grants Breakthrough Designation to Glytec’s Glucommander Pediatrics for Newborns and Infants
Hyperglycaemia is common among ill newborns and premature infants and is associated with poor outcomes in this patient group. Credit: Yuriy K / Shutterstock.com.
The US Food and Drug Administration (FDA) has granted breakthrough device designation to Glytec's proposed insulin-dosing algorithm, Glucommander Pediatrics, intended for hospitalised newborns and infants under two years of age. The algorithm is designed to provide dosing recommendations for continuous intravenous insulin infusion in critically ill neonates with life‑threatening or irreversibly debilitating conditions.
What the Tool Targets
Glucommander Pediatrics is aimed at neonates and infants who require continuous IV insulin to manage severe hyperglycaemic states. Clinical situations the algorithm would support include:
- Diabetic ketoacidosis (DKA)
- Hyperglycaemic hyperosmolar state (HHS)
- Persistent or refractory hyperglycaemia
- Hyperglycaemia of prematurity in critically ill infants
Why This Matters
Hyperglycaemia is common among critically ill newborns and premature infants and is associated with poorer outcomes. Although continuous intravenous insulin infusion remains the standard of care, dosing is challenging in this population because infant physiology is highly variable and specialised clinical tools are limited.
'Glucose values are among the most frequently collected measures in hospitalised patients, recorded across nearly every unit and service line,' Glytec CEO Patrick Cua said. 'Care for newborns and infants sits at the far end of that problem, where the physiology is least stable, and the available tools are fewest. We have spent 20 years making insulin dosing safer for hospitalised patients, and the smallest patients have been last in line the entire time.'
The proposed product would be prescription-only and distinct from Glytec's existing Glucommander platform, extending the company's technology into neonatal intensive care units (NICUs) and paediatric intensive care units (PICUs). Glytec highlights that technology-enabled insulin-titration protocols used in adult ICUs have improved glucose control and reduced hypoglycaemia compared with manual, paper-based protocols, and it expects a similarly measured pathway for patients under two years.
Regulatory And Company Background
The FDA's Breakthrough Devices Program is intended to speed development and patient access to devices that may provide more effective treatment for life‑threatening or irreversibly debilitating conditions. Glucommander first received FDA clearance in 2006; since then Glytec has obtained additional clearances for both intravenous and subcutaneous insulin dosing and extended paediatric indications in 2012 to include patients aged two to 17. Glytec currently serves more than 400 hospitals and health systems.
Glucommander Pediatrics will undergo further clinical validation and regulatory review as Glytec advances the product toward market and seeks to demonstrate safety and effectiveness in this particularly vulnerable population.
Help us improve.
